Upcoming Research Roles
Find out more about research roles with EASL Consortium for Regenerative Hepatology
Create a 5% bio-engineered liver mass in order to develop “implantable liver tissue” for the treatment of inherited hepatic metabolic disorders.
Create bioengineered bile ducts to be used in liver transplant and congenital biliary diseases.
Create a 30% bio-engineered liver mass for transplantation in patients with acute or acute-on-chronic liver failure.
1st Symposium of the EASL Consortium of Regenerative Hepatology
May 5, 2022It is our great honor to announce our 1st Symposium on “Regenerative Hepatology: Past Achievements and Current Ch ...
The 2021 winner of the Albert Geerts Fellowship
April 22, 2022For the 2021 call of the Albert Geerts Fellowship we have the pleasure to announce Dr. Floris Roos, who will be joining ...
Announcement of the first two winners of the Albert Geerts Fellowship
March 18, 2020After a careful evaluation process performed by three external reviewers led by Prof. Massimo Colombo, we proudly an ...
The Albert Geerts Fellowship, the new EASL Consortium for Regenerative Hepatology Fellowship
March 18, 2020Albert (Bert) Geerts born on 29th September, 1952 died on 24th January, 2009. He was one of the most renowned liver cell ...
Research Think Tank
August 12, 2019EASL Regenerative Hepatology: Take-off event Last April 10th 2019 in Vienna at the International Liver Meeting 2019, ...
Kick-off Meeting of the EASL Regenerative Hepatology Consortium
July 31, 2019On January 22nd 2019, the European Association for the Study of the Liver (EASL) – Regenerative Hepatology Consort ...